SCHEMBL7228372

SCHEMBL7228372

CCN(CC)C(=O)c1cc(S(=O)(=O)Cc2ccccc2)c(Cl)cc1N(CC)CCN(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CA12 O43570 4/20 0.40
▸ CA1 P00915 4/20 0.40
▸ CA2 P00918 4/20 0.40
▸ CA4 P22748 4/20 0.40
▸ CA6 P23280 4/20 0.40
▸ CA5A P35218 4/20 0.40
▸ CA7 P43166 4/20 0.40
▸ CA9 Q16790 4/20 0.40
▸ CA13 Q8N1Q1 4/20 0.40
▸ CA14 Q9ULX7 4/20 0.40
▸ CA5B Q9Y2D0 4/20 0.40
▸ CA3 P07451 3/20 0.40
▸ LMNA P02545 1/20 0.39
▸ OPRD1 P41143 2/20 0.39
▸ OPRM1 P35372 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6250573 0.81 TSHR (0.46) TSHRSMN1; SMN2CA12CA1CA2
SCHEMBL30480658 0.79 CCR1 (0.38) OPRD1OPRM1HTR6ALDH1A1
SCHEMBL6250677 0.67 TSHR (0.61) TSHRSMN1; SMN2CA12CA1CA2
SCHEMBL31670552 0.63 CA12 (0.71) TSHRSMN1; SMN2CA12CA1CA2
SCHEMBL7288618 0.63 TSHR (0.61) TSHRLMNAMAPK1ALDH1A1
SCHEMBL11008942 0.63 CISD1 (0.60) CA12CA1CA2CA4CA6
SCHEMBL18423559 0.62 CA1 (0.68) CA12CA1CA2CA4CA6
SCHEMBL7228486 0.62 TSHR (0.47) TSHRSMN1; SMN2CA12CA1CA2
SCHEMBL143826 0.62 TP53 (0.65) TSHRLMNAMAPK1ALDH1A1
SCHEMBL29128098 0.62 TSHR (0.49) TSHRSMN1; SMN2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552048-B2 For use in therapy of hyperlipidemia and arteriosclerotic disorders AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-22 — — US disclosed
US-20020147337-A1 Process for preparing sulfonylcarboxamide derivatives AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-10-10 — — US disclosed
US-20020072520-A1 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-06-13 — — US disclosed
US-6342512-B1 ANTILIPEMIC AGENTS, ATHERIOSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072520-A1 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals LIPA, CES1, SLC5A1 TSHR 1486/4885SMN1; SMN2 2022/4885CA12 3421/4885
US-20020147337-A1 Process for preparing sulfonylcarboxamide derivatives SLC5A1, CES1, SLC5A2 TSHR 2243/4885SMN1; SMN2 1548/4885CA12 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback